Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

The Immunotherapy Surge

July 2021 – Immunotherapy
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
University Distinguished Service Professor of Breast Cancer,
Professor of Surgery, Johns Hopkins University School of Medicine
Co-Developer of Work Stride—Managing Cancer at Work
Johns Hopkins Healthcare Solutions

For decades, well, actually centuries, we have been using 3 methods to get rid of cancer and keep it at bay—cut it out (by surgery), burn it (with radiation), or poison it (with chemotherapy). Granted, there are now, and have been for several decades, additional methods, such as biologic drugs known as targeted therapies, and of course hormonal therapy, that we have also used for a very long time.

It has taken a great deal of scientific knowledge and research, which have been in progress for more than 2 decades, to develop a new category of cancer treatment—immunotherapy.

Immunotherapy uses your own body’s immune system to get rid of cancer cells in your body. This type of therapy may sound simple, but trust me, it is not. Immunotherapy is probably the most complex therapy that has ever been developed. And although you may think that it should be free of side effects, it is not. It does have side effects, some of which may be severe, but overall immunotherapy has fewer side effects than some other types of cancer therapies.

A lot happens within your body when this type of therapy is infused into your system to jumpstart your immune system and target it to do its job in eliminating cancer cells. Does it always work? No. But there is promise today and good evidence that it is extending lives, especially for those with advanced cancers, who otherwise would be looking at a short period of time to still be survivors.

This can be seen in this special issue in the 2 patient stories surrounding 2 different types of advanced cancer. These stories highlight the survival benefits that these patients received through the use of immunotherapy. Specifically, each of them has been using a type of immunotherapy known as a PD-1 or PD-L1 inhibitor, because they inhibit certain proteins, called PD-1 or PD-L1, on some cancer cells. By blocking these proteins, these immunotherapies enhance the immune response against cancer cells, thereby improving the patient’s chance of better outcomes and survival.

We hope you learn a great deal from this special issue. Share it with other people, too, so they could be enlightened about this new type of cancer treatment that holds huge promise today and in the future.

Recommended For You